Meet Ignyta’s Scientific Advisory Board

The Ignyta Scientific Advisory Board provides objective scientific and clinical advice to help inform the optimal development of Ignyta’s precision therapeutics for the potential benefit of patients with cancer.

Pasi Janne of Ignyta's Scientific Advisory Board

Pasi Jänne, M.D., Ph.D.

Pasi Jänne is a distinguished leader in thoracic oncology and is actively involved in the successful development of molecularly targeted therapies for cancer patients.

Dr. Jänne is the Director of the Lowe Center for Thoracic Oncology and Senior Physician at the Dana-Farber Cancer Institute (DFCI), Scientific Director of the Belfer Institute for Applied Cancer Science, and Professor of Medicine at Harvard Medical School. His main research interests include the study of oncogenic alterations, including epidermal growth factor receptor mutations, in non-small cell lung cancer and their impact on the sensitivity and resistance to targeted therapies.

Dr. Jänne received his M.D. and Ph.D. from the University of Pennsylvania in 1996. He completed postgraduate training in internal medicine at Brigham and Women’s Hospital and in medical oncology at DFCI in 2001.

Mario Sznol of Ignyta's Scientific Advisory Board

Mario Sznol, M.D.

Mario Sznol has an international reputation in cancer drug development, a recognized oncology leader whose interests include cancer immunotherapy, drug development for cancer, and treatment of patients with melanoma and renal cell carcinoma. He is working to expand the opportunities for clinical trials at the Yale Cancer Center, particularly those focusing on immunotherapy and novel agents.

Dr. Sznol is currently Professor of Medicine, and Leader, Melanoma/RCC Disease-Associated Research Team at the Yale faculty in medical oncology, which he joined in 2004. He graduated from Rice University in 1979 and from Baylor College of Medicine, Houston, Texas in 1982. He completed internship and medicine residency programs at Baylor College of Medicine, Houston, Texas in 1985. After completing a fellowship in medical oncology at Mount Sinai College of Medicine in NYC in 1987, he joined the NCI as a Senior Investigator in the Investigational Drug Branch (IDB), Cancer Therapy Evaluation Program (CTEP). He was Head of the Biologics Evaluation Program, IDB, CTEP, from 1994-1999, and in 1999, was appointed to the position of Vice President of Clinical Development for Vion Pharmaceuticals in New Haven, CT.

Victor Velculescu of Ignyta's Scientific Advisory Board

Victor Velculescu, M.D., Ph.D.

Victor Velculescu is internationally known for his discoveries in genomics and cancer research. He and his colleagues have pioneered a variety of genomic technologies and were the first to perform genome-wide sequence analyses in human cancer. These analyses identified a variety of genes not previously known to be involved in neoplasia, including PIK3CA as one of the most highly mutated genes in human tumors. These discoveries provide insights into the mechanistic features and pathways underlying human cancer and provide new opportunities for individualized diagnostic and therapeutic approaches.

Dr. Velculescu is Co-Director of Cancer Biology and Professor of Oncology and Pathology at the Johns Hopkins University Kimmel Cancer Center. He completed his B.S. at Stanford University and his M.D., Ph.D. degrees at Johns Hopkins University School of Medicine. Dr. Velculescu is a former member of the Board of Directors of AACR, is Co-Leader of the Stand Up to Cancer Colorectal Dream Team, has served as a member of scientific advisory boards of the Starr Cancer Consortium, Quintiles, Helicos Biosciences, Inostics, and SoftGenetics, and is a co-founder of Personal Genome Diagnostics.